Skip to main content

Table 4 Sensitivity and positive predictive value (PPV), with 95% confidence interval (95%CI), of triage strategies for high-grade cervical abnormalities among women living with HIV who tested HPV positive on the provider-collected (Provider) or self-collected (Self) specimen for women living with HIV. Sensitivity was calculated for all endpoints diagnosed, not just among HPV-positive women. N+, number of positives by that triage strategy; NHG, number of high-grade cervical abnormalities interpretation who tested positive by that triage strategy

From: A comparison of screening tests for detection of high-grade cervical abnormalities in women living with HIV from Cameroon

  Provider Self
   Se PPV    Se PPV
N+ NHG % 95%CI % 95%CI N+ NHG % 95%CI % 95%CI
HPV+ 223 47 95.9% 86.0–99.5% 20.7% 15.2–25.9% 257 45 91.8% 80.4–97.7% 17.5% 13.1–22.7%
HPV16+ 47 18 36.7% 23.4–51.7% 38.3% 24.5–53.6% 57 17 34.7% 21.7–49.6% 29.8% 18.4–43.4%
HPV16/18/45+ 95 30 61.2% 46.2–74.8% 31.6% 22.4–41.9% 118 29 59.2% 44.2–73.0% 24.6% 17.1–33.4%
VIA+ 56 21 42.9% 28.8–57.8% 37.5% 24.9–51.5% 54 20 38.8% 25.2–53.8% 37.0% 24.3–51.3%
HPV16+ and VIA+ 16 10 20.4% 10.2–34.3% 62.5% 35.4–84.8% 14 9 18.4% 8.8–32.0% 64.3% 35.4–87.2%
HPV16/18/45+ and VIA+ 27 15 30.6% 18.3–45.4% 55.6% 35.3–74.5% 28 15 30.6% 18.3–45.4% 53.6% 33.9–72.5%
HPV16+ or VIA+ 87 29 59.2% 44.2–73.0% 33.3% 23.6–44.3% 97 28 57.1% 42.2–71.2% 28.9% 20.1–39.0%
HPV16/18/45+ or VIA+ 124 36 73.5% 58.9–85.1% 29.0% 21.2–37.9% 144 34 69.4% 54.6–81.7% 23.6% 16.9–31.4%